GlassScriptPhysician profile
Jason A Franks
NPI 1407848922
$7,062.57
in general payments reported to CMS, 2019-2025
41 companies · $802 in 2025
The $802 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $826 · 2021: $877 · 2022: $965 · 2023: $1,273 · 2024: $1,253 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,328.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $644.67 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $631.17 | 2019-2025 | |
| Pfizer INC. | $540.85 | 2019-2025 | |
| Novo Nordisk INC | $537.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $435.61 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $354.18 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $353.28 | 2019-2025 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $326.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $315.14 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $307.85 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.05 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $245.37 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.65 | 2019-2023 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $233.52 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $228.00 | 2022-2025 | Freestyle Libre 3, Assurity |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Franks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.